查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030130

自動注射器市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、適應症、最終用戶、地區和競爭對手分類，2021-2031年

Autoinjectors Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product, By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球自動注射器市場預計將從 2025 年的 101.2 億美元成長到 2031 年的 226.1 億美元，複合年成長率為 14.34%。

這些專用醫療設備旨在幫助患者自行注射精確劑量，通常使用彈簧注射器進行肌肉或皮下注射。推動這一市場成長的主要因素是類風濕性關節炎在全球範圍內的日益普遍，這些疾病需要定期或即時進行注射治療。此外，患者對便利的自我治療方法日益成長的需求，以及生物相似藥和生物製藥的普及，也促進了市場的發展。

市場概覽
預測期 2027-2031
市場規模：2025年 101.2億美元
市場規模：2031年 226.1億美元
複合年成長率：2026-2031年 14.34%
成長最快的細分市場 一次性自動注射器
最大的市場 北美洲

市場擴張的主要障礙在於設計和製造這些先進設備本身固有的複雜性和高昂成本，而嚴格的監管核准程序更使情況雪上加霜。這些障礙會阻礙新進入者，並顯著延長產品上市時間。關於推動自行注射設備需求的關鍵患者群體，國際糖尿病聯盟 (IDF) 報告稱，到 2025 年，全球將有 5.89 億成年人患有糖尿病。

市場促進因素

全球自體免疫疾病和慢性疾病的日益增多是自動注射器市場的主要驅動力，也因此增加了對便捷易用的自行注射方案的需求。多發性硬化症、糖尿病和類風濕性關節炎等疾病通常需要精準且規律的注射治療，這使得自動注射器成為提高患者用藥依從性和整體健康水平的重要工具。這些慢性疾病日益成長的影響直接推動了對操作簡便的給藥方式的需求。例如，根據美國疾病管制與預防中心（CDC）的數據，截至2026年3月11日，美國18歲及以上成年人中約有3,980萬人將患有糖尿病。

推動市場發展的另一個關鍵因素是標靶治療和生物製藥研發管線的擴張，因為許多此類先進藥物最好透過自動注射器等自行注射裝置給藥。製藥業對這些最先進治療的巨額投資自然催生了對相應精準給藥機制的需求。例如，Fierce Pharma在2026年2月報道稱，禮來公司旗下Zepbound和Mounjaro兩款產品2025年的總合銷售額達到365億美元，占公司總收入的56%。此外，諾和諾德2025年年度報告也顯示，與自動注射器使用相關的領域呈現強勁成長，以固定外匯計算，其總銷售額成長10%，達到3,090.64億丹麥克朗。

市場挑戰

先進自動注射器系統的設計和製造本身就非常複雜且高成本，加之嚴格的監管核准流程，嚴重阻礙了市場發展。巨額的研發和製造成本必然導致零售價格上漲，可能限制其價格的可負擔性和病患的取得途徑，尤其是在價格敏感型消費者和新興市場。此外，這些財務壁壘也為希望進入該行業的新創公司和小型企業帶來了巨大挑戰，進而抑制了創新，並縮小了消費者可選擇的自動注射器種類。

此外，嚴格的區域法規環境要求進行徹底的評估、詳細的記錄保存和漫長的審查階段。這些要求顯著延長了新型自動注射器上市所需的時間，從而推遲了患者獲得必要的自我治療的時間。 2025 年歐洲醫療技術協會 (MedTech Europe) 的一項調查凸顯了這一問題，該調查顯示，在醫療設備法規 (MDR) 實施後，主要醫療設備製造商選擇歐盟作為其主要上市地區的可能性降低了約 33%。這些與合規相關的延誤減緩了市場准入速度，增加了總研發成本，並最終阻礙了全球自動注射器產業的整體成長。

市場趨勢

改變全球自動注射器產業的關鍵趨勢之一是連網技術的應用。這使得關注點從簡單的藥物輸送轉向全面的患者參與和用藥依從性追蹤。這些智慧型裝置配備藍牙等功能，能夠自動記錄注射資料、提供個人化提醒，並安全地將資訊傳輸給醫療專業人員。這些進步旨在透過提供患者用藥依從性和給藥方法的即時數據來改善臨床療效，最終促進更高品質的慢性病自我管理。例如，2026年1月，Geresheimer公司發布了“Gx InMonit”，這是一款用於自動注射器的數位附件，旨在指導用戶完成注射過程，透過視覺和聽覺提示確認注射成功，並使用行動電話網路將數據傳輸到雲端。

大容量給藥機制的進步是另一個重要趨勢，旨在滿足日益成長的高劑量皮下給藥需求，尤其是複雜的生物製藥。雖然傳統的自動注射器適用於小劑量、精確給藥，但不斷出現的新治療方法需要能夠給藥超過1毫升（通常為10毫升或更多）的工具。這項發展對於將以往需要靜脈注射的治療方案轉變為更便捷的居家自我護理至關重要。例如，2026年1月，《醫藥商業》雜誌報道稱，BD公司與ten23 health公司合作推出了BD Libertas穿戴式注射器，該設備可使用5毫升或10毫升的玻璃藥筒進行大容量皮下給藥。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球自動注射器市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（一次性自動注射器、可重複使用自動注射器{預填充、空}）
    • 適應症（類風濕性關節炎、多發性硬化症、糖尿病、過敏性休克等）
    • 依最終使用者（居家醫療、醫院/診所、門診手術中心）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美自動注射器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲自動注射器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區自動注射器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲自動注射器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲自注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球自動注射器市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Eli Lilly and Company
  • SHL Medical AG
  • AbbVie Inc
  • Amgen Inc
  • Owen Mumford Limited
  • Ypsomed AG
  • Teva Pharmaceutical Industries Ltd
  • Biogen Inc.
  • Viatris Inc
  • Pfizer, Inc.
  • Gerresheimer AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 7341

The Global autoinjectors market is forecast to expand from USD 10.12 billion in 2025 to USD 22.61 billion by 2031, reflecting a 14.34% compound annual growth rate (CAGR). These specialized medical devices are designed to help patients independently administer exact medication doses, generally utilizing a spring-loaded syringe for intramuscular or subcutaneous delivery. A major catalyst for this growth is the rising worldwide incidence of chronic conditions like rheumatoid arthritis, diabetes, and anaphylaxis, which require regular or immediate injectable treatments. Furthermore, the market is bolstered by a growing patient inclination toward accessible self-treatment methods and the wider use of biosimilar and biologic drugs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.12 Billion
Market Size 2031USD 22.61 Billion
CAGR 2026-203114.34%
Fastest Growing SegmentDisposable Auto-injectors
Largest MarketNorth America

A notable obstacle to market expansion is the inherent intricacy and high expense associated with designing and producing these sophisticated tools, which is further complicated by strict regulatory clearance procedures. These hurdles can hinder new entrants and severely extend the time required to reach the market. Highlighting a core patient base driving the need for self-injection devices, the International Diabetes Federation (IDF) reported that 589 million adults worldwide were living with diabetes in 2025.

Market Driver

The Global increase in autoimmune and chronic conditions is a primary catalyst for the autoinjectors market, amplifying the demand for practical and readily available self-injection options. Diseases like multiple sclerosis, diabetes, and rheumatoid arthritis frequently necessitate exact and regular injectable treatments, positioning autoinjectors as vital instruments for enhancing patient compliance and overall well-being. This mounting impact of chronic diseases directly fuels the need for intuitive medication delivery methods. To illustrate, the U.S. Centers for Disease Control and Prevention (CDC) reported that roughly 39.8 million American adults aged 18 and older were living with diabetes as of March 11, 2026.

Another vital driver for the market is the growing pipeline of targeted treatments and biologics, given that many of these sophisticated drugs are optimally administered through self-injection tools such as autoinjectors. Heavy financial commitments by the pharmaceutical sector into these cutting-edge therapies naturally generate a need for corresponding, highly accurate delivery mechanisms. As an example, Fierce Pharma noted in February 2026 that the combined 2025 sales of Eli Lilly's Zepbound and Mounjaro hit USD 36.5 billion, representing 56% of the company's total revenue. Additionally, indicating strong expansion in areas linked to autoinjector usage, Novo Nordisk's 2025 Annual Report revealed a 10% rise in total sales at Constant Exchange Rates (CER), reaching DKK 309,064 million.

Market Challenge

Market progress is notably hindered by the inherent complications and high costs associated with engineering and producing sophisticated autoinjector systems, alongside strict regulatory clearance protocols. The steep expenses of development and manufacturing inevitably lead to higher retail prices, potentially limiting affordability and patient access, especially within price-conscious demographics and emerging economies. Furthermore, these monetary hurdles present a daunting challenge for startups and smaller enterprises attempting to break into the industry, consequently constraining innovation and narrowing the variety of autoinjector options accessible to consumers.

Additionally, rigorous regulatory environments in different regions necessitate thorough evaluations, detailed record-keeping, and lengthy assessment phases. Such obligations drastically extend the timeline required to introduce a novel autoinjector, pushing back patient access to essential self-treatment therapies. Highlighting this issue, a 2025 survey by MedTech Europe found that large medical device makers' inclination to use the European Union as their primary launch region dropped by roughly 33% after the Medical Device Regulation was implemented. These compliance-related hold-ups increase total creation expenses while delaying market entry, thereby suppressing the broader growth of the global autoinjectors sector.

Market Trends

A major trend transforming the global autoinjectors industry is the incorporation of connected technologies, which moves the emphasis beyond simple drug administration toward holistic patient involvement and compliance tracking. Equipped with capabilities such as Bluetooth, these intelligent devices facilitate the automated logging of injection statistics, tailored alerts, and the safe transfer of information to medical professionals. Such advancements strive to improve clinical results by supplying immediate data on patient compliance and administration methods, ultimately encouraging superior independent management of ongoing illnesses. For example, in January 2026, Gerresheimer introduced the Gx InMonit, a digital attachment for autoinjectors created to steer users through the injection steps, verify successful delivery through audio-visual cues, and send data to the cloud using cellular networks.

The progression of large-volume drug delivery mechanisms is another prominent trend, meeting the rising demand for administering sizable medication doses, especially intricate biologics, subcutaneously. While traditional autoinjectors were tailored for minor, set-dose applications, the broadening range of new therapies now demands tools that can dispense quantities exceeding 1 mL, frequently reaching 10 mL or higher. This evolution is vital for shifting treatments that once mandated intravenous drips into accessible, home-based self-care. To illustrate, Pharmaceutical Commerce reported in January 2026 that BD partnered with ten23 health to bring the BD Libertas wearable injector to market, a device engineered for substantial subcutaneous dosages utilizing 5 mL or 10 mL glass cartridges.

Key Market Players

  • Eli Lilly and Company
  • SHL Medical AG
  • AbbVie Inc
  • Amgen Inc
  • Owen Mumford Limited
  • Ypsomed AG
  • Teva Pharmaceutical Industries Ltd
  • Biogen Inc.
  • Viatris Inc
  • Pfizer, Inc.
  • Gerresheimer AG

Report Scope

In this report, the Global Autoinjectors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoinjectors Market, By Product

  • Disposable Auto-injectors
  • Reusable Auto-injectors

Autoinjectors Market, By Indication

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other

Autoinjectors Market, By End User

  • Homecare Settings
  • Hospitals & Clinics
  • Ambulatory Surgical Centers

Autoinjectors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoinjectors Market.

Available Customizations:

Global Autoinjectors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Autoinjectors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Disposable Auto-injectors, Reusable Auto-injectors {Prefilled, Empty})
    • 5.2.2. By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other)
    • 5.2.3. By End User (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Autoinjectors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Autoinjectors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Autoinjectors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Autoinjectors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By End User

7. Europe Autoinjectors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Autoinjectors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. France Autoinjectors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Autoinjectors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Autoinjectors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Autoinjectors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By End User

8. Asia Pacific Autoinjectors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Autoinjectors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Autoinjectors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Autoinjectors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Autoinjectors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Autoinjectors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By End User

9. Middle East & Africa Autoinjectors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Autoinjectors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Autoinjectors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Autoinjectors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By End User

10. South America Autoinjectors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Autoinjectors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Autoinjectors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Autoinjectors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Autoinjectors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. SHL Medical AG
  • 15.3. AbbVie Inc
  • 15.4. Amgen Inc
  • 15.5. Owen Mumford Limited
  • 15.6. Ypsomed AG
  • 15.7. Teva Pharmaceutical Industries Ltd
  • 15.8. Biogen Inc.
  • 15.9. Viatris Inc
  • 15.10. Pfizer, Inc.
  • 15.11. Gerresheimer AG

16. Strategic Recommendations

17. About Us & Disclaimer